Literature DB >> 35230581

Prediction of Recurrence Pattern of Pancreatic Cancer Post-Pancreatic Surgery Using Histology-Based Supervised Machine Learning Algorithms: A Single-Center Retrospective Study.

Koki Hayashi1, Yoshihiro Ono1, Manabu Takamatsu2, Atsushi Oba1, Hiromichi Ito1, Takafumi Sato1, Yosuke Inoue1, Akio Saiura1,3, Yu Takahashi4.   

Abstract

BACKGROUND: Patients with pancreatic cancer (PC) have poor prognosis and a high incidence of recurrence. Since further treatment is applicable for specific recurrent events, it is important to predict recurrence patterns after surgery. This study aimed to identify and predict early and late recurrence patterns of PC using a histology-based machine learning model. PATIENTS AND METHODS: Patients who underwent upfront curative surgery for PC between 2001 and 2014 were included. The timing of recurrence and prognosis of each first recurrence site were examined. A histology-based supervised machine learning method, which combined convolutional neural networks and random forest, was used to predict the recurrence and respective sites of metastasis. Accuracy was evaluated using area under the receiver operating characteristic curve (AUC).
RESULTS: In total, 524 patients were included. Recurrence in the liver accounted for 47.8% of all recurrence events in the first year after surgery. Meanwhile, recurrence in the lung occurred later and could become apparent more than 5 years post-surgery, with indications for further surgery. In terms of substantial distant organ metastases, liver and lung metastases were identified as representative early and late recurrence events. The predictive AUCs of the machine learning model for training and test data were 1.000 and 0.861, respectively, and for predicting nonrecurrence were 1.000 for both.
CONCLUSIONS: We identified the liver and lung as early and late recurrence sites, which could be distinguished with high probability using a machine learning model. Prediction of recurrence sites using this model may be useful for further treatment of patients with PC.
© 2022. Society of Surgical Oncology.

Entities:  

Year:  2022        PMID: 35230581     DOI: 10.1245/s10434-022-11471-x

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  42 in total

1.  Primary Recurrence in the Lung is Related to Favorable Prognosis in Patients with Pancreatic Cancer and Postoperative Recurrence.

Authors:  Biao Zheng; Kenoki Ohuchida; Zilong Yan; Takashi Okumura; Takao Ohtsuka; Masafumi Nakamura
Journal:  World J Surg       Date:  2017-11       Impact factor: 3.352

2.  Patterns, Timing, and Predictors of Recurrence Following Pancreatectomy for Pancreatic Ductal Adenocarcinoma.

Authors:  Vincent P Groot; Neda Rezaee; Wenchuan Wu; John L Cameron; Elliot K Fishman; Ralph H Hruban; Matthew J Weiss; Lei Zheng; Christopher L Wolfgang; Jin He
Journal:  Ann Surg       Date:  2018-05       Impact factor: 12.969

3.  Cancer statistics, 2020.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2020-01-08       Impact factor: 508.702

Review 4.  Meta-analysis of recurrence pattern after resection for pancreatic cancer.

Authors:  M Tanaka; A L Mihaljevic; P Probst; M Heckler; U Klaiber; U Heger; M W Büchler; T Hackert
Journal:  Br J Surg       Date:  2019-08-27       Impact factor: 6.939

Review 5.  Pancreatic Cancer Arising From the Remnant Pancreas: Is It a Local Recurrence or New Primary Lesion?

Authors:  Daisuke Hashimoto; Akira Chikamoto; Toshiro Masuda; Shigeki Nakagawa; Katsunori Imai; Yo-Ichi Yamashita; Howard A Reber; Hideo Baba
Journal:  Pancreas       Date:  2017-10       Impact factor: 3.327

6.  Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01).

Authors:  Katsuhiko Uesaka; Narikazu Boku; Akira Fukutomi; Yukiyasu Okamura; Masaru Konishi; Ippei Matsumoto; Yuji Kaneoka; Yasuhiro Shimizu; Shoji Nakamori; Hirohiko Sakamoto; Soichiro Morinaga; Osamu Kainuma; Koji Imai; Naohiro Sata; Shoichi Hishinuma; Hitoshi Ojima; Ryuzo Yamaguchi; Satoshi Hirano; Takeshi Sudo; Yasuo Ohashi
Journal:  Lancet       Date:  2016-06-02       Impact factor: 79.321

7.  Radiologically occult metastatic pancreatic cancer: how can we avoid unbeneficial resection?

Authors:  Atsushi Oba; Yosuke Inoue; Yoshihiro Ono; Shoichi Irie; Takafumi Sato; Yoshihiro Mise; Hiromichi Ito; Yu Takahashi; Akio Saiura
Journal:  Langenbecks Arch Surg       Date:  2019-11-28       Impact factor: 3.445

8.  Concomitant Intraductal Papillary Mucinous Neoplasm in Pancreatic Ductal Adenocarcinoma Is an Independent Predictive Factor for the Occurrence of New Cancer in the Remnant Pancreas.

Authors:  Ryota Matsuda; Yoshihiro Miyasaka; Yoshihiro Ohishi; Takeo Yamamoto; Kiyoshi Saeki; Naoki Mochidome; Atsushi Abe; Keigo Ozono; Koji Shindo; Takao Ohtsuka; Chie Kikutake; Masafumi Nakamura; Yoshinao Oda
Journal:  Ann Surg       Date:  2020-05       Impact factor: 12.969

9.  Implications of the Pattern of Disease Recurrence on Survival Following Pancreatectomy for Pancreatic Ductal Adenocarcinoma.

Authors:  Vincent P Groot; Georgios Gemenetzis; Alex B Blair; Ding Ding; Ammar A Javed; Richard A Burkhart; Jun Yu; Inne H Borel Rinkes; I Quintus Molenaar; John L Cameron; Elliot K Fishman; Ralph H Hruban; Matthew J Weiss; Christopher L Wolfgang; Jin He
Journal:  Ann Surg Oncol       Date:  2018-06-14       Impact factor: 5.344

Review 10.  Different clinical presentations of metachronous pulmonary metastases after resection of pancreatic ductal adenocarcinoma: Retrospective study and review of the literature.

Authors:  Martin Lovecek; Pavel Skalicky; Josef Chudacek; Marek Szkorupa; Hana Svebisova; Radmila Lemstrova; Jiri Ehrmann; Bohuslav Melichar; Tharani Yogeswara; Dusan Klos; Radek Vrba; Roman Havlik; Beatrice Mohelnikova-Duchonova
Journal:  World J Gastroenterol       Date:  2017-09-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.